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Abstract
Background: The HIV-1 p6 Gag protein regulates the final abscission step of nascent virions from the cell
membrane by the action of two late assembly (L-) domains. Although p6 is located within one of the most
polymorphic regions of the HIV-1 gag gene, the 52 amino acid peptide binds at least to two cellular budding
factors (Tsg101 and ALIX), is a substrate for phosphorylation, ubiquitination, and sumoylation, and mediates the
incorporation of the HIV-1 accessory protein Vpr into viral particles. As expected, known functional domains mostly
overlap with several conserved residues in p6. In this study, we investigated the importance of the highly
conserved serine residue at position 40, which until now has not been assigned to any known function of p6.
Results: Consistently with previous data, we found that mutation of Ser-40 has no effect on ALIX mediated rescue
of HIV-1 L-domain mutants. However, the only feasible S40F mutation that preserves the overlapping pol open
reading frame (ORF) reduces virus replication in T-cell lines and in human lymphocyte tissue cultivated ex vivo.
Most intriguingly, L-domain mediated virus release is not dependent on the integrity of Ser-40. However, the S40F
mutation significantly reduces the specific infectivity of released virions. Further, it was observed that mutation of
Ser-40 selectively interferes with the cleavage between capsid (CA) and the spacer peptide SP1 in Gag, without
affecting cleavage of other Gag products. This deficiency in processing of CA, in consequence, led to an irregular
morphology of the virus core and the formation of an electron dense extra core structure. Moreover, the defects
induced by the S40F mutation in p6 can be rescued by the A1V mutation in SP1 that generally enhances
processing of the CA-SP1 cleavage site.
Conclusions: Overall, these data support a so far unrecognized function of p6 mediated by Ser-40 that occurs
independently of the L-domain function, but selectively affects CA maturation and virus core formation, and
consequently the infectivity of released virions.
Background
The Gag polyprotein Pr55 of HIV-1 comprises the main
structural components that are essential and sufficient
for the formation of virus like particles (VLPs). Follow-
ing synthesis in the cytoplasm, the Gag polyproteins are
targeted to the plasma membrane where they assemble
into immature budding particles. Concurrent with
assembly and release of nascent virions, the Pr55 Gag
precursor is cleaved by the autocatalytically activated
viral protease (PR), generating the matrix (MA, p17),
c a p s i d( C A ,p 2 4 ) ,n u c l e o c a p s i d( N C ,p 7 ) ,a n dt h ep 6
protein. This processing ultimately leads to structural
rearrangement of Gag molecules within the virion and
the formation of the typical cone shaped core structure,
characteristic for a mature infectious particle [1]. MA
mediates the plasma membrane targeting of Gag poly-
proteins and, after cleavage, lines the inner shell of the
mature virion. CA forms the conical core shell encasing
NC, which regulates packaging and condensation of the
viral genome [2-6]. The C-terminal p6 domain of Pr55,
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amino acids, comprises a quite complex structural and
functional organization and contains two distinct late
assembly (L-) domains that regulate efficient separation
of assembled virions from the cell surface. L-domains
function as docking sites for components of ESCRT
(endosomal sorting complex required for transport), cel-
lular multi-protein complexes that are normally involved
in the endocytotic recycling of cell surface receptors and
in cytokinesis [4,7-17].
The L-domain activity of p6 is mainly driven by the
7PTAP
10 motif that is responsible for the recruitment of
the primary budding factor Tsg101 (tumor susceptibility
gene 101) to the virus assembly site [15,18-20]. Another
region of p6 involves the residues
36YPLASL
41, compris-
ing a cryptic YPXnL-type L-domain, which forms a
degenerated version of the YPDL L-domain motif
(YPXnL, n = 3) found in equine infectious anemia virus
(EIAV). This secondary L-domain in p6 represents a
binding site for another cellular budding factor, AIP1/
ALIX (ALG-2 interacting protein 1/X, ALIX is used
hereafter), a multifunctional ESCRT-associated regulator
of intracellular protein transport [13,21]. In addition to
the interaction with cellular ESCRT components, p6
mediates the incorporation of the HIV-1 accessory pro-
tein Vpr into virus particles. This incorporation was
shown to be dependent on three motifs in p6, the
15FRFG
18 motif, the
34ELY
36 motif, and the
41LXXLF
45
motif [22-24].
Besides these well characterized interactions, p6 con-
tains several highly conserved amino acids, some of
which were shown or proposed to undergo posttransla-
tional modification. In this study, we show that muta-
tion of the highly conserved Ser residue in position 40
(Ser-40) leads to an irregular core assembly of the
released virions, a reduced infectivity, and, thus, a dis-
turbed virus replication capacity. The results support a
novel function of p6 in virus maturation that occurs
independently of L-domain function.
Results
Mutation of Ser-40 has no effect on folding of p6
HIV-1 p6 is located within one of the most polymorphic
regions of the HIV-1 gag gene, yet the 52 amino acid
peptide harbors one of the densest region of protein
interacting domains in HIV-1. Figure 1A gives an over-
view of the previously reported binding domains of cel-
lular (Tsg101, ALIX, ERK-2, SUMO-1, ubiquitin) and
viral (Vpr) proteins within p6 from HIV-1NL4-3 and their
relationship to the primary and secondary structures
[25]. An alignment of consensus sequences, derived
from all HIV-1 group M subtypes, revealed that the
known functional domains overlap - as expected - with
conserved residues in p6.
While the PTAP L-domain is highly conserved, the
conservation within the ALIX binding site varies to
some extent (Figure 1). The ALIX-binding motif has
been defined as (L)[FY]PX1-3LXX[IL] [21,26,27] and cor-
responds in p6 derived from HIV-1NL4-3 [28] to
35LYPLASLRSL
44, in which essential residues are in
bold. Interestingly, the three amino acid motif
35LYP
37
at the start of the binding region is only poorly con-
served (Figure 1) while both, Leu-41 and Leu-44, are
highly conserved. These two residues together, with the
downstream Phe-45, comprise the LXXLF binding
domain for the HIV-1 accessory protein Vpr. From pre-
vious structural and mutational analysis, it can be con-
cluded that Thr-39 and Ser-40 do not directly
participate in the binding of p6 to ALIX [21,27,29].
Consistently, Thr-39 is not conserved, while in contrast,
Ser-40 is highly conserved among HIV-1 group M iso-
lates, indicating a function other than ALIX binding.
To investigate a potential function of Ser-40 in p6, the
residue was mutated in the infectious molecular clone
HIV-1NL4-3 [28] and an otherwise isogenic R5-tropic
derivative thereof carrying the 005pf135 V3 loop region
in Env [30]. In order to obtain replication competent
viruses, the mutation was introduced in a way that does
not affect the overlapping pol-ORF. In particular, Ser-40
of p6 overlaps in the pol-ORF with the cleavage site
between the transframe p6*p r o t e i na n dP R .T h eo n l y
p o s s i b i l i t yt ol e a v et h epol-ORF unaffected was to
exchange Ser-40 for Phe, creating the mutant S40F.
Considering this limitation in mutating p6, we wanted
proof that the non-conservative S40F exchange does not
disturb the secondary structure of p6 in the respective
region. To ascertain whether the S40F mutation alters
the C-terminal helix of p6, the synthetic (s)p6
23-52S40F
peptide was characterised by
1H NMR spectroscopy
[25]. Recently, we solved the structure of sp6
23-52 by
NMR and found that the C-terminal fragment adopts
the same structure as the full length molecule sp6
1-52.
Therefore, it was legitimate to analyse the structure of
the mutant and compare it with the wt molecule. After
complete assignment of the
1H resonances of the NMR
spectra of the peptide, NOE cross peaks important for
secondary structure identification were identified. The
observation of NHi -N H i+1,N H i -N H i+2, aHi -N H i+ 2,
aHi -N H i+ 3, aHi -N H i+ 4 and aHi - bHi+3NOEs,
which are indicative of helical secondary structure,
showed that, similarly to wt sp6
23-52, sp6
23-52S40F has a
preference for an a-helical structure involving residues
Ile-31 - Asp-48 under hydrophobic membranous condi-
tions (50% aqueous trifluorethanol (TFE) solution). Sub-
stitution of Ser-40 with Phe did not change the position
or number of residues included in the C-terminal helix
compared with wt sp6
23-52, and their structures appear
to be similar. This is confirmed from a comparison of
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random coil values (Figure 2), which indicates that the
substitution slightly stabilizes the region of the
C-terminal helix comprised of residues Leu-41 - Leu-44
proximal to Phe-40.
Mutation of Ser-40 in HIV-1 compromises virus replication
The finding that Ser-40 in p6 is highly conserved raises
the question whether this amino acid is important for
the function of p6 in HIV-1 replication. To investigate
this, comprehensive replication studies of HIV-1 carry-
ing mutation of Ser-40 in p6 were conducted in T cells
and primary lymphocytes. Purified virus stocks of wt
HIV-1NL4-3 and the S40F mutant were generated in
293T cells and normalized for p24 content. First, paral-
lel cultures of CEM T-cells were infected with 20 and
50 ng of input virus, respectively, and samples of culture
supernatants collected every other day were analyzed for
secretion of virus particles by measuring the virus asso-
ciated reverse transcriptase (RT) activity. The resulting
replication profiles are shown in Figure 3A and 3B.
Mutation of Ser-40 resulted in a diminished replication
capacity of HIV-1, which is observed as a delayed onset
of virus replication (Figure 3A). Furthermore, increase
of the input virus to 50 ng resulted in a forward shift of
the peak of virus replication. Yet, the overall virus pro-
duction was still reduced, indicating altogether a com-
promised replication capacity of the Ser-40 mutant of
p6 (Figure 3B). To further evaluate the relevance of
Ser-40 in p6, replication studies were conducted in lym-
phoid cells, derived from human tonsillary tissue, culti-
vated as aggregate cultures (HLAC) [31]. The HLAC
system has been reported to be of comparable value to
that of previously described human lymphoid tissue cul-
tures (HLT) where virus replication is studied in tissue
blocks [32,33]. Generally, both HLACs and HLTs, sup-
port productive HIV-1 replication independently of the
coreceptor tropism and do not require artificial exogen-
ous activation of host cells [32,33]. Parallel cultures of
HLAC were infected with X4-tropic or R5-tropic HIV-
1NL4-3 carrying mutation of Ser-40. Samples of culture
supernatant were harvested every third day, and secre-
tion of viral particles was determined by measuring the
virus associated RT activity. The resulting replication
profiles obtained in tissue samples, derived from two
different donors for X4-tropic strains, are shown in Fig-
ure 3C and 3E, and for R5-tropic variants in Figure 3D
and 3F. Consistent with results obtained in CEM cells
(Figure 3A, 3B), mutation of Ser-40 resulted in a
reduced replication capacity of both X4-tropic and R5-
tropic viruses.
Mutation of Ser-40 in p6 does not affect virus release but
disturbs CA maturation
To analyze whether the decreased replication capacity of
the Ser-40 mutant is due to either a reduction of virus
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Figure 1 Location and conservation of important functional sites in HIV-1 p6. Primary sequence of p6 derived from the isolate HIV-1NL4-3
[28] and structural domains according to previous work [25]. Indicated are previously identified (ERK-2) phosphorylation sites [55], attachment
sites for ubiquitin (Ub) [56] and SUMO-1 [57], and binding domains for Tsg101 [15,18,20,58], ALIX [13] and Vpr [22]. The consensus sequences of
p6 proteins derived from the M-group viruses http://www.hiv.lanl.gov were aligned and conserved residues are boxed in grey.
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Page 3 of 16particle production or to a loss of infectivity of the
released virions, we first investigated whether Ser-40 is
somehow involved in the L-domain mediated assembly
and release of virus particles. Virus release kinetics were
studied by pulse chase metabolic labeling experiments.
Parallel cultures of HeLa cells were transfected with the
env-deleted HIV-1NL4-3 subgenomic expression vector
pNLenv1 [34,35], encoding either wt p6 or the S40F
mutant. Cells were pulse labeled with [
35S]-methionine
f o r1 5m i n u t e sa n dc h a s e df o ru pt o4h o u r s .A te a c h
time point indicated, samples of cells were harvested,
and VLPs released into the supernatants were collected
by centrifugation and processed for immunoprecipita-
tion with Gag-specific antibodies. Immunoprecipitated
proteins were separated by SDS-PAGE and analyzed by
fluorography (Figure 4A). The amounts of Gag recov-
ered from virus and cell lysates were quantified by
image analysis. The release of VLPs was calculated as
percentage of Gag proteins found in the virus fraction,
relative to the total amount of Gag recovered from virus
and cell fractions and plotted as a function of time
(Figure 4B). Clearly, virus release was not affected by
mutation of Ser-40. However, quantification of the CA
processing products p25 and p24 revealed a significant
reduction in the processing rate of p25 to p24 for the
S40F mutant (Figure 4C). Thus, Ser-40 somehow regu-
lates the proteolytic maturation of the CA-SP1 Gag pro-
cessing intermediate, without affecting the overall
efficiency of virus release.
S40F mutation reduces specific infectivity of the virions
Having shown that mutation of Ser-40 in p6 does not
affect L-domain mediated virus release but disturbs
maturation of CA, we analyzed the role of this Ser residue
in maturation of progeny virions. To measure the specific
infectivity of the mutant, HeLa TZM-bl cells were infected
with individual virus stocks standardized for p24 content
and infectivity was determined by b-galactosidase assay.
Consistent with virus replication data, mutation of Ser-40
reduced the infectivity by approximately 6-10 fold when
compared to the wt virus (Figure 5).
Mutation of Ser-40 has no effect on ALIX mediated virus
release
Ser-40 residue is located within the previously identified
36YPLASL
41 ALIX binding sequence, although shown
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Figure 2 Mutation of Ser-40 does neither affect the secondary structure of p6, nor the interaction with ALIX. A) Chemical shift
differences (ppm) of the a-protons between the experimental values and those for residues in a random coil for sp6
23-52wt and sp6
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Figure 3 Replication of HIV-1NL4-3 wt and S40F mutant in CEMs and HLAC. CEM cells were inoculated with purified virus equivalent to
20 ng (A) or 50 ng (B) of p24 bearing indicated mutations, and medium was collected every two days. For replication analyses in HLAC, X4
tropic (C and E) and R5 tropic (D and F), 1 ng of p24 of purified virus carrying indicated mutations was used for infection and release of viral
particles was determined in the supernatant every third day (C and D: donor A, E and F: donor B).
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Page 5 of 16not to be involved in the interaction with ALIX directly
[21,29]. It was further reported that mutation of either
Leu-41 or Leu-44 directly adjacent to Ser-40 exhibit a
similar phenotype to that observed for the S40F mutant
in terms of CA processing [36]. Therefore, it was legiti-
mate to investigate whether mutation of Ser-40 affects
the functional interaction between ALIX and p6. We
first examined the ability of ALIX to rescue the release
of an HIV-1ΔPTAP L-domain mutant by overexpression
in the absence of the Ser-40 [21,37]. The S40F mutation
was cloned into a variant of HIV-1NL4-3 where the
PTAP motif was replaced by LIRL (HIV-1ΔPTAP [38]).
293T cells were cotransfected with plasmids encoding
ALIX and either HIV-1ΔPTAP or HIV-1ΔPTAP/S40F.A s
control, cells were cotransfected with HIV-1ΔPTAP/ΔYP,
where the ALIX binding site YPX3L was replaced by
SRX3L. As previously reported, this mutation completely
abrogates ALIX mediated rescue of release of HIV-
1ΔPTAP variants [21]. Gag processing and release of
infectious virions were determined 24 hours post trans-
fection by Western blot and single round infection of
TZM-bl cells. The results shown in Figure 6A demon-
strate that in the presence of the intact ALIX binding
site in p6, overexpression of ALIX dramatically stimu-
lated virus release by more than 10-fold as shown by
Western blot and single round infection of TZM-bl cells
(Figure 6A, lanes 1 and 2). Consistent with previous
results [21,27], the mutation of the minimal ALIX bind-
ing motif further reduced virus release even below the
residual budding of an HIV-1ΔPTAP mutant (Figure 6A,
lane 5), and completely prevents rescue of the HIV-
1ΔPTAP variant by overexpression of ALIX (Figure 6A,
lane 6) [21]. Mutation of Ser-40 also reduced the resi-
dual release of the HIV-1ΔPTAP mutant (Figure 6A, lane 3).
In contrast to the ΔYP mutation, in the presence of the
S40F mutation, overexpression of ALIX still efficiently res-
cued the release of the HIV-1ΔPTAP mutant (Figure 6A,
lane 4 upper panel). However, overexpression of ALIX did
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Figure 4 Gag processing and release of virions. (A) Phosphorimages of SDS-PAGE gels of immunoprecipitations of
35S pulse-chase-labeled
Gag protein immunoprecipitates are presented for cell and viral lysates from HeLa cells transiently transfected with either pNLenv or pNLenv
S40F. (B) Percentage of Gag released from the cell presented as the amount of Gag found in virus particles versus the total amount of Gag
recovered form cell and virus lysates. (C) The rate of CA processing was estimated by calculating the ratio of mature CA p24 versus the CA
precursor p25 detected in the cell and virus lysates at different time points.
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Page 6 of 16not restore the infectivity of the S40F mutant virions (Fig-
ure 6A, lane 4 lower panel), indicating that the loss of
infectivity induced by mutation of Ser-40 occurs indepen-
dently of the ALIX-p6 interaction.
To further uncouple the phenotype induced by S40F
mutation from the underlying L-domain function of the
ALIX binding site, we investigated whether ALIX can
rescue the infectivity of the S40F mutant in the context
of a functional PTAP motif. To this end, 293T cells
were co-tranfected with HIV-1 encoding either wt p6 or
the S40F mutant and ALIX. Release of infectious virions
was determined 24 hours post transfection by single
round infection of TZM-bl cells. Consistent with pre-
vious results, the S40F mutation reduced the infectivity
of released virions by ~5-fold (Figure 6B, 1 and 3).
While overexpression of ALIX had no significant influ-
ence on the infectivity of wt HIV-1 (Figure 6B, 2), ALIX
also could not restore the reduced infectivity of the
S40F mutant (Figure 6B, 4).
In order to determine whether the ALIX mediated
rescue of the HIV-1ΔPTAP variant of the S40F is still
comparable to the control, we measured the require-
ment of ALIX for HIV-1ΔPTAP release at varying ALIX
concentrations. 293T cells were cotransfected with HIV-
1ΔPTAP and increasing amounts of ALIX expression
plasmids. Subsequent determination of virus release by
W e s t e r nb l o t( F i g u r e7 A )s h o w e dt h a ti nt h ep r e s e n c e
of the S40F mutation similar amounts of ALIX were
required to stimulate virus release (Figure 7A and 7B).
Notably, ALIX substantially improved the processing of
CA of the HIV-1ΔPTAP mutant. In contrast, CA proces-
sing of the HIV-1ΔPTAP/S40F mutant was further
impaired, compared to the HIV-1ΔPTAP mutant, and was
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Figure 6 S40F mutation has no effect on ALIX mediated virus
release. (A) Rescue of budding of the Ser-40 mutant by ALIX. Virus
release, Gag processing, and exogenous expression of ALIX were
analyzed by Western blot (upper panel). Ribosomal P0 antigen (RP0)
was used as loading control. The amounts of infectious units
released from the cells were analyzed by b-galactosidase
quantification after infection of TZM-bl cells (lower panel). Shown
are virus infectivities relative to the HIV-1ΔPTAP control ± SD. Lane 1
shows HIV-1ΔPTAP mutant cotransfected with the empty control
vector, lane 2 shows HIV-1ΔPTAP mutant cotransfected with a FLAG-
ALIX expression plasmid, lanes 3 and 4 show the HIV-1ΔPTAP/ΔYP
double mutant cotransfected with the empty control plasmid and
the vector expressing V5-POSH, respectively, lanes 5 and 6 show the
HIV-1ΔPTAP/ΔYP double mutant cotransfected with the empty control
plasmid and the vector expressing V5-POSH, respectively. (B)
Overexpression of ALIX does not rescue infectivity of the S40F
mutant. The amounts of infectious units released from the cells
analyzed were by b-galactosidase quantification after infection of
TZM-bl cells. Shown are virus infectivities relative to the HIV-1
control ± SD. 1: HIV-1 contransfected with the empty control vector,
2: HIV-1 cotransfected with a FLAG-ALIX expression plasmid, 3: HIV-
1S40F cotransfected with the empty control vector, 2: HIV-1S40F
cotransfected with a FLAG-ALIX expression plasmid.
Figure 5 Specific infectivity of HIV-1NL4-3 wt and p6-mutants.
TZM-bl cells were infected with purified virus preparations
standardized for p24. Infectious titers were determined by
measuring b-galactosidase activity as described in Materials and
Methods (RLU: relative light units).
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Page 8 of 16not rescued by overexpression of ALIX (Figure 7A).
This was further supported by the notion that the infec-
tivity of the S40F mutant virions was substantially
reduced and could not be restored by overexpression of
ALIX (Figure 7C). Taken together, the data indicate that
the interaction of p6 with ALIX is not affected by repla-
cing the conserved Ser-40 by Phe, and the phenotype
induced by this mutation occurs independently of the
ALIX mediated L-domain function of p6 in this region.
The S40F mutation does neither affect cleavage of Gag
products, other than CA, nor incorporation of Env
In order to rule out the possibility that mutation of Ser-
40 also affects processing of Gag proteins other than
CA, virus preparations were analyzed by Western blot-
ting using antibodies specific for NC or MA. Virus par-
ticles prepared by transient transfection of 293T cells
were purified by centrifugation through a 20% sucrose
cushion and standardized for p24 content by ELISA.
Equal amounts of p24 were loaded on SDS-PAGE and
analyzed by Western blotting. The amount of MA and
NC proteins in S40F mutant viruses was similar to that
of wt virions, indicating that maturation of these Gag
proteins is not affected by the S40F mutation (Figure
8A). Even with the relatively low resolution of the SDS-
PAGE system, the disturbed processing of CA from p25
to p24 was detectable (Figure 8A).
It was shown previously that mutations of p6 in this
area, in particular, mutations of Tyr-36 and Leu-41 pro-
duce mutants that fail to package Env proteins into
virus particles [39]. Since Ser-40 is located directly adja-
cent to Leu-41, we wanted to exclude that the reduced
replication capacity and infectivity of the S40F mutant is
due to reduced Env incorporation. To this end, purified
virions standardized for p24 content were analyzed by
Western blotting using Env specific antibodies. As
shown in Figure 8B, the S40F mutation had no influence
on Env incorporation into virus particles.
Electron microscopy analysis of p6 S40F mutants
Next, we examined the effects of the S40F mutation on
assembly, release, and virion morphology by thin-section
electron microscopy (Figure 9). HeLa cells transiently
transfected with plasmids encoding HIV-1NL4-3 and
mutants thereof were drawn into cellulose capillary
tubes 24 hours post transfection. The cellulose capillary
tubes retain secreted virions, thereby obviating the need
for centrifugation steps that usually affect the native vir-
ion structure. In agreement with our biochemical data,
accumulation of virions tethered at the cell membrane,
a phenotype commonly observed for L-domain mutants
in p6, was not observed for the S40F mutant (data not
shown). However, and most intriguingly, mutation of
Ser-40 in p6 led to the formation of aberrant virus parti-
cles, characterized by irregularly shaped viral cores and
the formation of closely neighboring electron-dense lat-
eral bodies, as indicated in Figure 9A. These irregularly
shaped cores and lateral bodies were not observed in
the wt and the ΔYP mutant, again indicating that this
phenotype occurs independently of the ALIX-Gag inter-
action. As we observed a deficiency in CA processing of
p25 to p24 in the virions containing the S40F mutation
(Figure 9), we investigated whether this defect in virus
core assembly is a consequence of imperfect CA proces-
sing. A previously characterized CA5 mutant was gener-
ated in HIV-1NL4-3 that is incapable of processing p25
to p24 and was shown to exhibit a similar defect of core
assembly [40]. Indeed, the phenotype observed for CA5
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resembles that of the S40F mutant (Figure 9A).
To evaluate quantitatively this morphological phenom-
enon, cores of 100 - 120 virons were counted and the
percentages of irregular core structures relative to wt
virions were calculated (Figure 9B). Obviously, mutation
of Ser-40 significantly increases the amount of virions
containing aberrant, irregularly shaped virus cores.
Moreover, the CA5 mutant, in which CA processing is
blocked completely, shows the same phenotype as that
of the S40F mutant, further supporting the notion that
Ser-40 governs the processing of CA by a yet unidenti-
fied mechanism.
Defect in CA maturation of the S40F mutant can be
rescued by mutation in the CA-SP1 cleavage site
As described above, the S40F mutation increases the ratio
of p25 to mature p24. Our data, together with previous
results from others, suggest that this disturbed CA pro-
cessing subsequently leads to an irregular morphology of
the virus core and thus, to reduced virus infectivity of the
virions. This prompted us to investigate, whether restor-
ing the CA processing by introducing specific mutations
into the CA-SP1 cleavage site can rescue the defects in
core assembly and infectivity induced by the S40F muta-
tion. It is known that the affinity of the PR to the clea-
vage site between CA and SP1 is weak compared to other
proteolytic cleavage sites in Gag [41,42]. The A1V muta-
tion in the SP1, which previously was identified to confer
resistance to the CA-maturation inhibitor Bevirimat [43],
enhances the affinity of the viral protease to the CA-SP1
cleavage site. Thus, the A1V mutation in SP1 was intro-
duced into the HIV-1NL4-3 backbone in combination with
the S40F mutation in p6. Western blot analysis of puri-
fied virions revealed that, by introducing the A1V muta-
tion, CA processing is substantially enhanced in both, the
wt and the S40F mutant virions (Figure 10A). Further-
more, the A1V/S40F mutant displayed a similar CA pro-
cessing compared to the wt.
Consequently, we wanted to examine whether this
enhanced CA processing affects virus core assembly.
Therefore, virion structure of the A1V mutants was ana-
lyzed by thin-section electron microscopy. Cores of
100 - 120 virons were counted and the percentages of
irregular core structures relative to wt virions were
calculated (Figure 10B). The S40F mutation again sub-
stantially increases the amount of virions containing
aberrant, irregularly shaped virus cores. The A1V muta-
tion had only marginal effects on the core morphology
of wt HIV-1. However, in the case of the S40F mutant,
introducing the A1V mutation largely improves virus
core assembly (Figure 10B).
Since enhancing the CA processing rate rescues the
defect of viral core assembly, we subsequently wanted to
analyze whether this improved core formation also
affects the infectivity of the virions. To measure the spe-
cific infectivity, HeLa TZM-bl cells were infected with
individual virus stocks standardized for p24 content and
infectivity was determined by b-galactosidase assay.
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ity of the virons by 4-fold (Figure 10C). Introducing the
A1V mutation enhances the specific infectivity of the
virions of the otherwise attenuated S40F mutant to
almost wt levels (Figure 10C), indicating that the defi-
ciency in CA processing is the major determinant for
the reduced infectivity of the S40F mutant.
Discussion
In this study we demonstrate that mutation of the highly
conserved Ser-40 interferes with Gag processing and
virus core formation. Although Ser-40 in HIV-1 p6 is
highly conserved among HIV-1 isolates, it is not involved
in any of the functional motifs described so far, neither
the ALIX nor the Vpr binding site. Therefore, it was
legitimate to speculate that Ser-40 is involved in another,
until now unrecognized function of p6. However, it
should be noted that the position of Ser-40 in the nucleo-
tide sequence of HIV-1 overlaps with the p6*/PR cleavage
site in the overlapping pol-ORF, which limits the prob-
ability of mutations in this respective area and might
contribute to the high conservation of this amino acid.
Nevertheless, our findings of a compromised replication
capacity and reduced infectivity of the Ser-40 mutant
viruses support the assumption that Ser-40 has an impor-
tant function directly associated with p6.
Notably, virus release kinetic was not reduced for the
S40F mutant providing first evidence that the L-domain
function of p6 is not affected by mutation of Ser-40.
This was supported further by the observation that the
ability of ALIX to rescue HIV-1ΔPTAP L-domain mutant
viruses was not influenced by the S40F mutation.
Although Ser-40 is located within the ALIX binding
region in p6, previous structural investigations indicated
that Ser-40 itself does not participate in the binding of
p6 to ALIX [21,27,29]. The fact that the Ser-40 mutant
was still fully active in terms of L-domain function
further supports the notion, that the mutation
introduced into p6 did not disturb the overall
structure of the molecule in this respective region.
In consistency, structural calculations indicated that the
non-conservative exchange of Ser-40 to Phe does not
change the ability of the molecule to adopt a helical
structure. In fact, the C-terminal a-helix is conserved in
the S40F mutant, as it was established by NMR studies
of the C-terminal peptides sp6
23-52.
Yet, as shown previously, the phenotypes induced by
mutations in the ALIX binding site are depending on
the type of amino acid that is mutated [36]. Mutation of
the
35LYP
37 sequences in the ALIX binding site reduces
release and infectivity of HIV-1 virions, which otherwise
exhibit normal Gag processing [27,36]. In contrast,
mutations of Leu-41 and Leu-44 have no impact on
virus release but increase the ratio of p25 to mature
p24, similar to the phenotype we observed for mutation
of Ser-40 [36]. Unlike the typical phenotype of L-
domain mutants, these mutants interfere somehow spe-
cifically with the final step in maturation of CA. It is
currently not clear, whether this phenotype is in some
way associated with the ALIX-p6 interaction. While
mutations of Leu-41 and Leu-45 disrupt binding to
ALIX, mutation of Ser-40 apparently has no influence
on this interaction. Thus, it might also be possible, that
this area in p6 harbors another function that, indepen-
dent of L-domain activity, requires a so far unrecognized
cellular interaction partner.
Maturation of the Gag processing intermediate p25 to
mature CA p24, e. g. the cleavage of the CA-SP1 junc-
tion by the PR, appears to be one of the last steps of
Gag processing [41,42]. It was previously demonstrated
that mutating the junction between CA and SP1, in
order to block cleavage of p25, leads to the production
of noninfectious viral particles with aberrant core mor-
phology [40]. In addition, treatment of virus producing
cells with 3-O-(3’-3’dimethylsuccinyl) betulinic acid
(BVM, Bevirimat, also known as PA-457 or DSB), a spe-
cific inhibitor that blocks PR-mediated cleavage between
CA and SP1, disturbed viral core formation [43]. Intri-
guingly, mutation of Ser-40 leads to an almost identical
aberrant virus core morphology as shown previously for
CA5 mutants. Both are characterized by misshapen core
structures and the formation of an electron dense lateral
body near the viral membrane. Previous studies already
indicated that maturation of HIV-1 virions, leading to
the typical cone shaped cores, is regulated by the
sequential, and highly ordered proteolytic cleavage of
Gag [40]. Apparently, the last step of Gag processing -
the cleavage of the CA-SP1 junction - is required for
capsid condensation. However, pulse chase data indicate
that the kinetic of cleavage of the CA-SP1 junction is
delayed, but not completely blocked inasmuch as the
mature CA accumulates over time. This indicates a
rather dynamic process in which the mutation of Ser-40
somehow delays the kinetic of CA maturation. This phe-
nomenon correlates with deficiencies in CA processing,
infectivity, and core morphology.
Recently published results from Müller et al. demon-
strate that even low amounts of Gag processing inter-
mediates interfere with HIV particle maturation in a
trans-dominant manner, with the final cleavage between
p24 and SP1 being of particular importance [44]. This
explains why the rather subtle effect on CA maturation
detected for Ser-40 mutants by Western blotting and
pulse chase analysis results in a substantial reduction of
virus core formation.
Interestingly, the effect of the S40F mutation appears
to be specific for the CA-SP1 cleavage inasmuch as
i) no other Gag processing deficiency could be detected
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cing the A1V mutation could restore the deficient core
formation, and, consequently, enhance infectivity. Thus,
it can be concluded that Ser-40 somehow regulates the
cleavage of the CA-SP1 junction and the subsequent
capsid condensation.
The molecular mechanism behind how Ser-40 regu-
lates the processing of Gag, in particular the cleavage of
the CA-SP1 junction, is still elusive so far. The pre-
viously described defects in Gag processing commonly
observed for L-domain mutants are believed to be linked
to the overall process of virus budding inasmuch as PR
activation and subsequent Gag processing occur conco-
mitantly with and shortly after release of virus particles
[45,46]. In the case of Ser-40, this can be excluded, as
the mutant S40F exhibits wt budding. However, Ser-40
in p6 and the CA-SP1 junction are separated by 123
amino acids in Pr55 and it remains elusive so far, how
both proteins can affect each other, either in the context
of Pr55 or after Gag processing. Our NMR experiments
demonstrated that the C-terminal structure of p6 is not
influenced by the S40F mutation. Therefore, one possi-
bility of the effect observed would be that the mutation
affects the Gag structure prior to initiation of Gag pro-
cessing, thereby reducing the cleavage efficiency of the
weakest cleavage site in Pr55. A prerequisite for this
scenario would be that p6 represents a structured Gag
domain and thus influence the folding the Pr55 polypro-
tein. Even though the 283 residue N-terminal part of
HIV-1 Gag including MA and CA has been solved by
NMR [47], the structure of the complete Pr55 has not
been determined hitherto. Although S40F does not
appear to affect the folding of the mature p6 protein, we
can not exclude that this mutation indeed affect the
overall structure of the PR55 polyprotein, which in turn
would reduce the processing efficiency, a phenotype we
clearly observed for the S40F mutant as a novel function
of p6.
Currently, there is no evidence of an intra-molecular
interaction between these domains in the Pr55 polypro-
tein. The p6 domain of the Pr55 represents a docking
site of several cellular and viral factors. Thus, since an
intramolecular interaction between CA and p6 appears
to be unlikely, it is conceivable to hypothesize that p6
harbors another interaction domain of a yet unknown
factor that, independently of the L-domains, regulates
processing of CA.
Conclusions
Overall, these data support a so far unrecognized func-
tion of p6 that occurs independently of the L-domain
function, does not affect virus release, but selectively
affects CA maturation, virus core formation, and thus,
infectivity.
Methods
Peptide synthesis and purification
The synthesis, purification and molecular characteriza-
tion of p6 and the related fragments derived from HIV-
1NL4-3 have been described in detail previously [25].
NMR Spectroscopy
2D
1H Total Correlation Spectroscopy (TOCSY), Corre-
lation Spectroscopy (COSY) and Nuclear Overhauser
enhancement spectroscopy (NOESY) NMR experiments
were performed at 600.13 MHz on a Bruker Avance
600 MHz instrument equipped with an UltraShield Plus
magnet and a triple resonance cryoprobe with gradient
unit. Individual samples were dissolved in 600 μl5 0 %
aqueous TFE-d2 at concentrations between 1-2 mM.
The 2D NMR experiments were performed at 300 K
without spinning with mixing times of 110 ms for the
TOCSY experiments and 250 ms for the NOESY
experiments, respectively. Efficient suppression of the
water signal was achieved with application of excitation
sculpting in the 1D
1Ha n dt h e2 D
1HT O C S Ya n d
NOESY NMR experiments.
1H signal assignments of
t h eN M Rs p e c t r aw e r ea c h i e v e db yi d e n t i f i c a t i o no ft h e
individual spin systems in the 2D
1H TOCSY spectra,
combined with observations of sequence-specific short-
distance crosspeaks (Ha-HN i, i+1) in the 2D
1H-
1H
NOESY spectra [48,49]. Readily recognizable spin sys-
tems were used as starting points for correlation of the
individual spin systems observed in the TOCSY and
NOESY spectra with individual residues in the peptide
sequences. Acquisition of data, processing and spectral
analysis were performed with Bruker Topspin 1.3
software.
Antibodies
Antibody specific for FLAG was obtained from Sigma,
the ribosomal P antigen specific antiserum from Immu-
novision Inc., the CA specific antiserum from Seramun.
The p6 specific antibody was described earlier [25]. The
anti-mouse, anti-rabbit, and anti-human IgG antibodies
coupled to horseradish peroxidase (HRP) were obtained
from Amersham.
DNA mutagenesis
Amino acid exchanges at Ser-40 in p6 were introduced
by site-directed mutagenesis using oligonucleotides con-
taining the indicated changes (S40F, ΔYP, and ΔPTAP)
and the Quick Change
® site directed mutagenesis kit
(Stratagene). The mutations were introduced in the X4-
tropic HIV-1NL4-3 infectious molecular clone [28] and
isogenic R5-tropic derivative thereof [30]. In order to
avoid taking biosafety measures, the mutations were also
introduced in two HIV-1NL4-3 based subgenomic expres-
sion vectors giving rise to noninfectious VLPs: the
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expression construct that carries a primer binding site
deletion, as well as two point mutations in the active
site of the RT coding region (pΔR [51]). All introduced
mutations did not lead to mutations in the overlapping
pol-ORF.
Cell culture
HeLa SS6, HeLa TZM-bl and 293T cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% (v/v) inactivated fetal calf serum
(FCS), 2 mM L-glutamine, 100 U/ml penicillin and
100 μg/ml streptomycin. CEM cells were maintained in
RPMI 1640 supplemented with 10% (v/v) inactivated
FCS, 2 mM L-glutamine, 100 U/ml penicillin and
100 μg/ml streptomycin. All media and compounds
were provided by Gibco.
Preparation and cultivation of primary cells
Human tonsils, removed during routine tonsillectomy,
were received a few hours after excision from the Olga-
hospital, Stuttgart, Germany, prepared and infected as
described earlier [32,33]. After washing the tonsils,
human lymphocyte aggregate cultures (HLAC) were
prepared by dividing the tonsils into tissue blocks of
2 - 3m ma n dg r i n d i n gt h et i s s u et h r o u g ht h es i e v eo fa
cell strainer (70 μm, BD Falcon) with a syringe plunger.
Cells were seeded in a 96 well plate at a concentration
of 2 × 10
6 cells per well. HLACs were cultured in RPMI
1640 supplemented with 15% (v/v) inactivated FCS, 2
mM L-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin, 2.5 μg/ml Fungizone, 1 mM sodium pyru-
vate, 1% (v/v) MEM non-essential amino acid solution
and 50 μg/ml gentamicin.
Western blot for protein analysis
HeLa SS6 cells were transiently transfected with the
appropriate DNA using Lipofectamine 2000™ (Invitro-
gen) according to the manufacturer’s protocol. For
ALIX cotransfection, 293T cells were transfected with
equal amounts of both DNAs and cells were harvested
24 h post transfection. Cells were lysed in cold RIPA
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholat, 0.1% Na-SDS,
5 mM EDTA, DNase, 1 mM PMSF and complete pro-
tease inhibitor cocktail (Boehringer Mannheim)), and
the lysates were cleared by centrifugation at 16000 × g
and 4°C for 10 min. RIPA-soluble proteins and VLPs
were separated in 10% SDS/PAA gels, according to
Laemmli [52], transferred onto PVDF membranes (GE
Healthcare) and probed with specific antibodies, fol-
lowed by enhanced chemiluminescence detection. For
internal controls, blots were stripped and re-incubated
with the appropriate antibody.
Metabolic labeling and immunoprecipitation
For pulse chase experiments, adherent cultures of trans-
fected HeLa SS6 cells were washed once with PBS and
starved for 30 min in methionine-free, serum-free RPMI
1640. Cells were pulse-labeled for 15 min with [
35S]-
methionine (3 mCi/ml; Amersham Life Sciences) and
chased for up to 4 h while shaking at 37°C in D-MEM,
supplemented with 10% FCS and 10 mM methionine.
At the indicated time points, cells and supernatants
were collected by centrifugation for 1 min at 16000 × g.
Virions were pelleted through a 20% (w/v) sucrose cush-
i o na n dl y s e di nT r i t o nw a s hb u f f e r( 5 0m MT r i s - H C l
pH 7.4, 300 mM NaCl, 0.1% Triton X-100, 1 mM
PMSF). Cells were lysed in RIPA buffer as described
above, containing additionally 5 mM N-ethylmaleimide
and 20 μM carbobenzoxyl-Leu-Leu-leucinal (zLLL;
Sigma). Gag proteins from precleared cell lysates and
lysed VLPs were recovered by immunoprecipitation
using a mixture of polyclonal rabbit anti-p6 and anti-
p24 antibodies prebound to protein G-Sepharose (GE
Healthcare). Samples were separated by SDS-PAGE on a
10% (w/v) acryl amide ProSieve gel (Cambrex
Bioscience), backed with Gel Bond film (FMC Biopro-
ducts). Following fixation for 1 h in 50% methanol and
10% acetic acid, gels were rinsed with water, soaked in
1 M sodium salicylic acid solution with 10% glycerol for
5 h and dried. Radioactivity in dried gels was quantified
using AIDA imaging software (Raytest).
Viruses
Virus containing cell culture supernatant was harvested
after 48 h and, after removal of residual cells by centri-
fugation, passed through a 0.45 μm pore-size filter.
Virus was pelleted through 20% (w/v) sucrose (16000 ×
g, 4°C, 90 min). Virus stocks were normalized for p24
content as quantified by a enzyme-linked immunosor-
bent assay (ELISA, Aalto, Dublin, Ireland) and aliquots
were stored at -80°C.
Infection of cells
For infection of T cell cultures, 1 × 10
7 cells were incu-
bated with 20 or 50 ng of p24, respectively, and super-
natant was collected every second day post infection.
Virus replication was assessed by quantification of the
virus-associated RT activity by [
32P]-TTP incorporation
using an oligo(dT)-poly(A) template as described [53].
For testing each virus in the HLAC from one donor,
1 ng of p24 was applied to 2 × 10
6 cells in 96 well for-
mat, and virus replication was assessed, as described for
T cell cultures, every third day post infection.
Viral infectivity assay
HeLa TZM-bl cells were seeded in 96 well format (4000
cells per well) and infected with standardized amount
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dextran sulphate was added to prevent further spread of
virus infection, and cells were incubated for further two
days. Infection was detected using a galactosidase screen
kit from Tropix as recommended by the manufacturer.
b-Galactosidase activity was quantified as relative light
units per second using an Orion Microplate Lumin-
ometer (Berthold).
Transmission electron microscopy (TEM)
Transfected HeLa SS6 cells were processed for transmis-
sion electron microscopy in the following way: 24 h post
transfection, cells were placed in cellulose capillary tubes
[54], cultivated for one more day, then fixed in 2.5% glu-
taraldehyde for 1 h at 37°C and stored for further pre-
paration at 4°C. Tubes were collected by centrifugation
and sealed by immersion in low-melting-point agarose.
The samples were post fixed with OsO4 (1% in distilled
water, 1 h), tannic acid (0.1% in Hepes 0,05 M, 30 min)
and uranyl acetate (1% in distilled water, 2 h) followed
by stepwise dehydration in a graded ethanol series and
embedding in epon resin, which was subsequently poly-
merized. Thin sections were prepared with an ultrami-
crotome (Ultracut S; Leica, Wetzlar, Germany) and
counterstained with uranyl acetate and lead citrate. The
sections were examined using a TEM 902 (Carl Zeiss
SMT AG) at 80 kV, and the images were digitized using
a slow-scan charge-coupled-device camera (Pro Scan;
Scheuring, Germany). The evaluation of the capsid mor-
phology was performed by using these images or directly
on the screen.
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